A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma by Yang, Eddy S., Deutsch, Eric, Mehmet, Altan, Fayette, Jerome, TAO, Yungan, Nabell, Lisle, Spencer, Sharon A., Wang, Xuejing A., Spoljoric, Elizabeth A., Zhang, Wei, Hynes, Scott M., Decker, Rodney L., Lin, Aimee K. Bence, William, William N.

Get full text

Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen by Poole, Andrew, Karuppiah, Vijaykumar, Hartt, Annabelle, Haidar, Jaafar N., Moureau, Sylvie, Dobrzycki, Tomasz, Hayes, Conor, Rowley, Christopher, Dias, Jorge, Harper, Stephen, Barnbrook, Keir, Hock, Miriam, Coles, Charlotte, Yang, Wei, Aleksic, Milos, Lin, Aimee Bence, Robinson, Ross, Dukes, Joe D., Liddy, Nathaniel, Van der Kamp, Marc, Plowman, Gregory D., Vuidepot, Annelise, Cole, David K., Whale, Andrew D., Chillakuri, Chandramouli

Get full text

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models by Lowery, Caitlin D, Dowless, Michele, Renschler, Matthew, Blosser, Wayne, VanWye, Alle B, Stephens, Jennifer R, Iversen, Philip W, Lin, Aimee Bence, Beckmann, Richard P, Krytska, Kateryna, Cole, Kristina A, Maris, John M, Hawkins, Douglas S, Rubin, Brian P, Kurmasheva, Raushan T, Houghton, Peter J, Gorlick, Richard, Kolb, E Anders, Kang, Min H, Reynolds, C Patrick, Erickson, Stephen W, Teicher, Beverly A, Smith, Malcolm A, Stancato, Louis F

Get full text

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer by Solomon, Benjamin J, Zhou, Cai Cun, Drilon, Alexander, Park, Keunchil, Wolf, Jürgen, Elamin, Yasir, Davis, Hannah M, Soldatenkova, Victoria, Sashegyi, Andreas, Lin, Aimee Bence, Lin, Boris K, F Loong, Herbert H, Novello, Silvia, Arriola, Edurne, Pérol, Maurice, Goto, Koichi, Santini, Fernando C

Get full text

Therapeutic high affinity T cell receptor targeting a KRAS G12D cancer neoantigen by Poole, Andrew, Karuppiah, Vijaykumar, Hartt, Annabelle, Haidar, Jaafar N, Moureau, Sylvie, Dobrzycki, Tomasz, Hayes, Conor, Rowley, Christopher, Dias, Jorge, Harper, Stephen, Barnbrook, Keir, Hock, Miriam, Coles, Charlotte, Yang, Wei, Aleksic, Milos, Lin, Aimee Bence, Robinson, Ross, Dukes, Joe D, Liddy, Nathaniel, Van der Kamp, Marc, Plowman, Gregory D, Vuidepot, Annelise, Cole, David K, Whale, Andrew D, Chillakuri, Chandramouli

Get full text

Abstract LB-200: Dose and schedule determination of the Chk1/2 inhibitor LY2606368 in patients with solid tumors by Bendell, Johanna C., Janku, Filip, Infante, Jeffrey, Jones, Suzanne, Burris, Howard, Golden, Lisa, Hynes, Scott M., Lin, Ji, Bence, Aimee K., Tse, Susan, Kurzrock, Razelle, Hong, David

Get full text